Home › Therapeutic areas › Metabolic › Bardet-Biedl Syndrome
Bardet-Biedl Syndrome (2 companies)
Companies with an active program in Bardet-Biedl Syndrome.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 2 | Phase 3 | $864M | 16 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | 1 | Approved | $7.78B | 14 |
No companies match.